Squarepoint Ops LLC Takes $986,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Squarepoint Ops LLC acquired a new position in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) during the second quarter, according to the company in its most recent filing with the SEC. The fund acquired 116,256 shares of the biopharmaceutical company's stock, valued at approximately $986,000. Squarepoint Ops LLC owned approximately 0.24% of Theravance Biopharma at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of TBPH. Gerber LLC purchased a new stake in Theravance Biopharma during the 4th quarter worth approximately $112,000. Wellington Management Group LLP raised its stake in Theravance Biopharma by 68.0% during the fourth quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company's stock valued at $3,227,000 after buying an additional 116,164 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Theravance Biopharma by 16.6% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,876 shares of the biopharmaceutical company's stock worth $474,000 after buying an additional 7,509 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Theravance Biopharma by 7.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 49,475 shares of the biopharmaceutical company's stock worth $444,000 after acquiring an additional 3,532 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System increased its holdings in shares of Theravance Biopharma by 28.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company's stock valued at $203,000 after acquiring an additional 4,990 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Price Performance

TBPH traded down $0.05 during midday trading on Monday, hitting $8.05. 188,074 shares of the company's stock traded hands, compared to its average volume of 372,308. The company has a market cap of $391.50 million, a PE ratio of -9.36 and a beta of 0.25. Theravance Biopharma, Inc. has a one year low of $7.44 and a one year high of $11.71. The stock's fifty day simple moving average is $8.32 and its 200-day simple moving average is $8.81.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last posted its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.25). The firm had revenue of $14.26 million for the quarter, compared to the consensus estimate of $15.81 million. Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. During the same period in the prior year, the company posted ($0.28) earnings per share. On average, research analysts expect that Theravance Biopharma, Inc. will post -1.04 EPS for the current year.

Analyst Ratings Changes

TBPH has been the topic of a number of recent research reports. TD Cowen reduced their price target on shares of Theravance Biopharma from $10.00 to $9.00 and set a "hold" rating on the stock in a research report on Tuesday, August 6th. Leerink Partnrs lowered Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 6th. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price target on shares of Theravance Biopharma in a research note on Monday, September 16th. StockNews.com downgraded Theravance Biopharma from a "buy" rating to a "hold" rating in a research report on Saturday, August 10th. Finally, Leerink Partners cut Theravance Biopharma from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $15.00 to $10.00 in a research note on Tuesday, August 6th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $13.75.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, major shareholder Eli Samaha purchased 999,800 shares of the company's stock in a transaction that occurred on Wednesday, August 7th. The stock was purchased at an average price of $7.80 per share, with a total value of $7,798,440.00. Following the completion of the transaction, the insider now directly owns 9,511,150 shares of the company's stock, valued at approximately $74,186,970. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Theravance Biopharma news, major shareholder Eli Samaha bought 999,800 shares of the firm's stock in a transaction dated Wednesday, August 7th. The shares were bought at an average price of $7.80 per share, for a total transaction of $7,798,440.00. Following the completion of the acquisition, the insider now owns 9,511,150 shares of the company's stock, valued at approximately $74,186,970. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Rhonda Farnum sold 4,000 shares of the firm's stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now owns 335,965 shares of the company's stock, valued at approximately $3,023,685. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.90% of the company's stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.